Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Anchiano Therapeutics, Inc","sponsor":"ChemomAb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Anchiano Therapeutics and Chemomab Announce Entry Into Definitive Merger Agreement","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II"},{"orgOrder":0,"company":"Anchiano Therapeutics, Inc","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","amount":"$45.5 million","upfrontCash":"Undisclosed","newsHeadline":"Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II"},{"orgOrder":0,"company":"Anchiano Therapeutics, Inc","sponsor":"ChemomAb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chemomab Completes Merger with Anchiano Therapeutics","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Anchiano Therapeutics, Inc

    Menu

    Anchiano Therapeutics, Inc

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Anchiano Therapeutics, Inc

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Chemomab Completes Merger with Anchiano Therapeutics

              Details:

              Chemomab expects to use net proceeds from this private placement to advance in parallel three Phase 2 clinical trials for its lead product, CM-101, a novel antibody for treating rare fibrotic conditions, as well as to further develop its earlier-stage pipeline.

              Lead Product(s): CM-101

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM-101

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: ChemomAb

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Merger March 16, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Anchiano Therapeutics, Inc

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing

              Details:

              Financing will be used to advance the Chemomab pipeline. Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity.

              Lead Product(s): CM-101

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM-101

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Cormorant Asset Management

              Deal Size: $45.5 million Upfront Cash: Undisclosed

              Deal Type: Financing March 15, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Anchiano Therapeutics, Inc

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Anchiano Therapeutics and Chemomab Announce Entry Into Definitive Merger Agreement

              Details:

              Merger brings lead compound CM-101, a first in class anti-CCL24 antibody into advanced clinical development for fibrosis-related diseases with significant unmet medical need.

              Lead Product(s): CM-101

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM-101

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: ChemomAb

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Merger December 15, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY